Applied Genetic Technologies Corp (AGTC) reported quarterly earnings results on Monday, May-9-2016. The company reported $0.11 earnings per share for the quarter, missing the analyst consensus estimate by $-0.27. Analysts had a consensus of $0.38. The company posted revenue of $12.00 million in the period, compared to analysts expectations of $13.18 million. The company’s revenue was up 4125.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.38 EPS.
Applied Genetic Technologies Corp closed down -0.16 points or -1.11% at $14.26 with 1,52,245 shares getting traded on Friday. Post opening the session at $14.5, the shares hit an intraday low of $14.03 and an intraday high of $14.61 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.